Gerald on Twitter when asked about RS @Mathhe
Post# of 30027
@MathhewReni
No. We are focused on execution of our plan, and particularly clinical data for Tollovir ahead of any Nasdaq listing. We have multiple bullets left to fire in the weeks and months ahead.
https://twitter.com/MathhewReni/status/142045...63173?s=20